Drug Profile
Research programme: anticancer therapeutics - BioMarin Pharmaceutical
Latest Information Update: 01 Apr 2011
Price :
$50
*
At a glance
- Originator LEAD Therapeutics
- Developer BioMarin Pharmaceutical
- Class
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 17 Nov 2009 LEAD is exploring partnering possibilities for LT 673
- 16 Sep 2009 Early research in Prostate cancer in China (unspecified route)
- 16 Sep 2009 Early research in Prostate cancer in USA (unspecified route)